BAXTER'S $448 MIL. SALE OF DIAGNOSTICS MANUFACTURING BUSINESSES
This article was originally published in The Gray Sheet
BAXTER'S $448 MIL. SALE OF DIAGNOSTICS MANUFACTURING BUSINESSES will help the company reduce its debt-to-capital ratio to about 40% by the end of 1994, according to Baxter. The company announced Oct. 3 a definitive agreement for the sale of its manufacturing operations to Bain Capital, expected to close before the end of the year. Baxter is retaining exclusive U.S. distribution fights to its diagnostics products businesses for five years.
You may also be interested in...
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.